Health disparities in breast cancer: biology meets socioeconomic status.

Abstract:

:Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negative (ERneg) tumors. ERneg tumors fail to respond to current established targeted therapies, whether for treatment or prevention. Subsets of the ERneg phenotype include those that are also negative for the progesterone receptor (PR) and HER2; these are called "triple negative" (TN) breast cancers. TN tumors frequently have pathological characteristics resembling "basal-like" breast cancers. Hence, the latter two terms are often used interchangeably; yet, despite extensive overlap, they are not synonymous. The ERneg, TN, and basal-like phenotypic categories are important because they carry worse prognoses than ER-positive (ERpos) tumors, in addition to lacking obvious molecular targets, such as HER2 and the ER, for known therapies. Furthermore, among premenopausal women the three subsets occur more frequently in women of African descent compared to white women with breast cancer. The contribution of these three subtypes of poor-prognosis tumors to the higher breast cancer mortality in black women is the focus of this review. We will attempt to clarify some of the issues, including risk factors, in terms of their contribution to that component of health disparities that involves biological differences in breast cancer between women of AA and white women.

authors

Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

doi

10.1007/s10549-010-0827-x

subject

Has Abstract

pub_date

2010-06-01 00:00:00

pages

281-92

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

121

pub_type

杂志文章,评审
  • Lack of efficacy of xeroradiography to preoperatively detect axillary lymph node metastases in breast cancer.

    abstract::Xeroradiography of the axilla was performed in 132 patients with operable breast cancer to investigate the status of the axillary lymph nodes. Pathologic findings were correlated with the results of clinical examination and xeroradiographic findings. Xeroradiography does not appear to have improved our ability to iden...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807590

    authors: Coopmans de Yoldi GF,Andreoli C,Costa A,Nessi R,Gilardoni L,Rasponi A

    更新日期:1983-01-01 00:00:00

  • Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

    abstract:PURPOSE:Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical parameter for Ki-67 interobserver performance. However, the maximum degree of variance among pathologis...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05112-9

    authors: Denkert C,Budczies J,Regan MM,Loibl S,Dell'Orto P,von Minckwitz G,Mastropasqua MG,Solbach C,Thürlimann B,Mehta K,Blohmer JU,Colleoni M,Müller V,Klauschen F,Ataseven B,Engels K,Kammler R,Pfitzner BM,Dietel M,Fasching

    更新日期:2019-08-01 00:00:00

  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

    abstract:PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05454-y

    authors: Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

    更新日期:2020-01-01 00:00:00

  • A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.

    abstract::Monitoring effective antiestrogenic activity of the triphenylethylenes in patients with breast cancer is usually determined by the duration of response. The pharmacokinetics of toremifene and tamoxifen have been shown to be highly variable but patient specific. In the present study, we developed a method to accurately...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01832356

    authors: DeGregorio M,Wurz G,Emshoff V,Koester S,Minor P,Wiebe V

    更新日期:1992-01-01 00:00:00

  • Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.

    abstract::Although new chemotherapeutic drugs for metastatic breast cancer (MBC) have been approved over the past decade, it is unclear whether this has changed the overall outcome of patients. This study assessed the clinical and economic impacts of these drugs. We retrospectively studied MBC patients receiving chemotherapy in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1311-3

    authors: Galy G,Labidi-Galy SI,Perol D,Bachelot T,Ray-Coquard I,Tredan O,Biron P,Latour JF,Blay JY,Guastalla JP,Favier B

    更新日期:2011-07-01 00:00:00

  • Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

    abstract:PURPOSE:This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS:The study comprised 126 index patients who met NCCN clinical criteria and te...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05985-9

    authors: Gomes R,Spinola PDS,Brant AC,Matta BP,Nascimento CM,de Aquino Paes SM,Bonvicino CR,Dos Santos ACE,Moreira MAM

    更新日期:2020-10-30 00:00:00

  • Microcysts and breast cancer: a study of biological markers in archival biopsy material.

    abstract::Breast cysts are associated with an increased risk of breast cancer. Some biomarkers such as estrogen receptor alpha (ERa), progesterone receptor (PR), and cyclin D1, show similar patterns of expression in epithelial cells lining breast cysts as malignant epithelial cells in local and invasive ductal breast cancer. We...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1019969730552

    authors: Tran DD,Lawson JS

    更新日期:2002-10-01 00:00:00

  • Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

    abstract:AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1010669403283

    authors: Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

    更新日期:2001-04-01 00:00:00

  • Cultured cell lines from human breast cancer biopsies and xenografts.

    abstract::Eighty-five breast cancer specimens were processed as part of a program in tumor acquisition, propagation, and preservation for biotherapy. Nine long-term culture cell lines were developed. Four cell lines were from solid tumor metastases, two lines were from pleural fluid specimens, and three were from xenograft tumo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806292

    authors: Lewko WM,Vaghmar R,Hubbard D,Moore M,He YJ,Chang L,Husseini S,Wallwork K,Thurman GB,Oldham RK

    更新日期:1990-12-01 00:00:00

  • Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

    abstract::Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant "window of opportunity" study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2223-1

    authors: Niraula S,Dowling RJ,Ennis M,Chang MC,Done SJ,Hood N,Escallon J,Leong WL,McCready DR,Reedijk M,Stambolic V,Goodwin PJ

    更新日期:2012-10-01 00:00:00

  • Spindle cell lesions of the breast--the pathologic differential diagnosis.

    abstract::Spindle cell lesions of the breast represent an interesting diagnostic problem, as the differential diagnoses are wide. Diagnosing this is particularly problematic but important when encountered in a needle core biopsy, as treatments of different entities are different. In the histologic assessment of spindle cell les...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-007-9652-2

    authors: Tse GM,Tan PH,Lui PC,Putti TC

    更新日期:2008-05-01 00:00:00

  • Energy balance in early breast cancer patients receiving adjuvant chemotherapy.

    abstract::Weight gain is a common problem amongst women receiving adjuvant chemotherapy for early breast cancer. We undertook a study to determine the causes of this weight gain. Prospective measurements of body mass and composition (skinfolds, bioelectrical impedance, total body potassium), energy balance (resting energy expen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000014037.48744.fa

    authors: Harvie MN,Campbell IT,Baildam A,Howell A

    更新日期:2004-02-01 00:00:00

  • The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography.

    abstract:PURPOSE:We studied which, age of the patient or density of the breast accounts for the sensitivity of mammography and ultrasonography (US). Furthermore we studied whether the overall impression on the density of the breast or the density in tumour area accounts for the sensitivity of mammography and ultrasonography. M...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1010627527026

    authors: Saarenmaa I,Salminen T,Geiger U,Heikkinen P,Hyvärinen S,Isola J,Kataja V,Kokko ML,Kokko R,Kumpulainen E,Kärkkäinen A,Pakkanen J,Peltonen P,Piironen A,Salo A,Talviala ML,Haka M

    更新日期:2001-05-01 00:00:00

  • Quality control for estrogen receptor quantification by dextran-coated charcoal assay: a single laboratory's experience.

    abstract::Wide fluctuations in results obtained by different laboratories for the content of estrogen receptors from a single source of tissue powder were reported by several investigators at the 1979 NCI Consensus Committee Meeting for Steroid Receptors in Breast Cancer and were further supported by data collected by our labor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805724

    authors: Raam S,Gelman R,Faulkner J,White GM,Cohen JL

    更新日期:1982-01-01 00:00:00

  • Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer.

    abstract::The activity of selective estrogen receptor modulators (SERMs) is not fully explained by an estrogen receptor (ER) switch model that simply turns estrogen activity on or off. A better understanding of the mechanisms involved in estrogen signaling and the development of drug resistance could help stratify patients into...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-009-0429-7

    authors: McCafferty MP,McNeill RE,Miller N,Kerin MJ

    更新日期:2009-08-01 00:00:00

  • Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

    abstract:PURPOSE:We conducted an exploratory biomarker study from a phase II clinical trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in HER2-negative metastatic breast cancer (BC) patients. METHODS:We performed targeted deep sequencing with a customized cancer gene panel and RNA expression assa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05400-y

    authors: Kim JY,Lee E,Park K,Im SA,Sohn J,Lee KS,Chae YS,Kim JH,Kim TY,Jung KH,Park YH,Breast Cancer Committee of the Korean Cancer Study Group.

    更新日期:2019-11-01 00:00:00

  • Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.

    abstract:PURPOSE:Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcome...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05352-3

    authors: Aleixo GFP,Williams GR,Nyrop KA,Muss HB,Shachar SS

    更新日期:2019-10-01 00:00:00

  • Sphingosine-1-phosphate, a novel second messenger involved in cell growth regulation and signal transduction, affects growth and invasiveness of human breast cancer cells.

    abstract::This review will focus on the role of sphingosine and its phosphorylated derivative sphingosine-1-phosphate (SPP) in cell growth regulation and signal transduction. We will show that many of the effects attributed to sphingosine in quiescent Swiss 3T3 fibroblasts are mediated via its conversion to SPP. We propose that...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666166

    authors: Spiegel S,Olivera A,Zhang H,Thompson EW,Su Y,Berger A

    更新日期:1994-01-01 00:00:00

  • Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.

    abstract:PURPOSE:The methods (IHC/FISH) typically used to assess ER, PR, HER2, and Ki67 in FFPE specimens from breast cancer patients are difficult to set up, perform, and standardize for use in low and middle-income countries. Use of an automated diagnostic platform (GeneXpert®) and assay (Xpert® Breast Cancer STRAT4) that emp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4889-5

    authors: Wu NC,Wong W,Ho KE,Chu VC,Rizo A,Davenport S,Kelly D,Makar R,Jassem J,Duchnowska R,Biernat W,Radecka B,Fujita T,Klein JL,Stonecypher M,Ohta S,Juhl H,Weidler JM,Bates M,Press MF

    更新日期:2018-11-01 00:00:00

  • CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.

    abstract::Cyclin D1 (CCND1), a key cell cycle regulatory protein that governs the cell cycle progression from G1 to S phase, can promote cell proliferation or induce growth arrest and apoptosis. Since the identification of a well-characterized functional polymorphism, G870A in exon 4 of CCND1, several molecular epidemiological ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-008-0195-y

    authors: Lu C,Dong J,Ma H,Jin G,Hu Z,Peng Y,Guo X,Wang X,Shen H

    更新日期:2009-08-01 00:00:00

  • Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.

    abstract:BACKGROUND:We have developed a decision analysis model that uses the results of available randomized controlled trials to model the natural history of early breast cancer and assess the potential clinical and financial effects of using adjuvant therapies. PATIENTS AND METHODS:The original model was used to assess the ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00662134

    authors: Hillner BE,Smith TJ,Desch CE

    更新日期:1993-01-01 00:00:00

  • Effect of social housing condition on heat shock protein (HSP) expression in the Shionogi mouse mammary carcinoma (SC115).

    abstract::Our previous studies have shown that social housing conditions can significantly alter the growth rate of the Shionogi mouse mammary carcinoma (SC115). The present study extended our investigations to the molecular level by examining stressor effects on the expression of a group of stress-responsive proteins, the heat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006314010958

    authors: Andrews HN,Kerr LR,Strange KS,Emerman JT,Weinberg J

    更新日期:2000-02-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract::We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-9503-3

    authors: Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期:2004-10-01 00:00:00

  • Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

    abstract::Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. At data cut-off, only 36 % of patients had pro...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10549-012-2192-4

    authors: Robertson JF,Lindemann JP,Llombart-Cussac A,Rolski J,Feltl D,Dewar J,Emerson L,Dean A,Ellis MJ

    更新日期:2012-11-01 00:00:00

  • Long-term outcome in young women with breast cancer: a population-based study.

    abstract:PURPOSE:Whether young age at diagnosis of breast cancer is an independent risk factor for death remains controversial, and the question whether young age should be considered in treatment decisions is still to be answered. METHODS:From a population-based cohort of 22,017 women with breast cancer, all women <35 years (...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3983-9

    authors: Fredholm H,Magnusson K,Lindström LS,Garmo H,Fält SE,Lindman H,Bergh J,Holmberg L,Pontén F,Frisell J,Fredriksson I

    更新日期:2016-11-01 00:00:00

  • Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

    abstract::This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1332-y

    authors: Masuda N,Iwata H,Rai Y,Anan K,Takeuchi T,Kohno N,Takei H,Yanagita Y,Noguchi S

    更新日期:2011-04-01 00:00:00

  • Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

    abstract:BACKGROUND:Gemcitabine (G) and vinorelbine (V) have favorable safety profile and antitumor activity in metastatic breast cancer. To exploit their different mechanism of action and lack of overlapping toxicity, we performed a phase I and II study of G and V in combination. PATIENTS AND METHODS:Fifty-three patients with...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1013034311284

    authors: Mariani G,Tagliabue P,Zucchinelli P,Brambilla C,Demicheli R,Villa E,Marchianò A,Valagussa P,Bonadonna G,Gianni L

    更新日期:2001-12-01 00:00:00

  • C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

    abstract::To investigate the expression levels of CXCL10 and CXCR3 in tumors from breast cancer patients randomized to adjuvant tamoxifen treatment or no endocrine treatment, in order to further study the connection to prognosis and prediction of tamoxifen treatment outcome. Immunohistochemistry on tissue microarrays from 912 b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-014-2933-7

    authors: Hilborn E,Sivik T,Fornander T,Stål O,Nordenskjöld B,Jansson A

    更新日期:2014-05-01 00:00:00

  • Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.

    abstract::The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2796-3

    authors: Liu Y,Zhou R,Baumbusch LO,Tsavachidis S,Brewster AM,Do KA,Sahin A,Hortobagyi GN,Taube JH,Mani SA,Aarøe J,Wärnberg F,Børresen-Dale AL,Mills GB,Thompson PA,Bondy ML

    更新日期:2014-01-01 00:00:00

  • Prognostic impact of breast cancer subtypes in elderly patients.

    abstract::We aimed to analyse the impact of breast cancer (BC) subtypes on the clinical course of disease with special emphasis on the occurrence of brain metastases (BM) and outcome in an elderly BC population. A total number of 706 patients ≥65 years receiving treatment for BC from 2007 to 2011 were identified from a BC datab...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3787-y

    authors: Bergen ES,Tichy C,Berghoff AS,Rudas M,Dubsky P,Bago-Horvath Z,Mader RM,Exner R,Gnant M,Zielinski CC,Steger GG,Preusser M,Bartsch R

    更新日期:2016-05-01 00:00:00